What is the clinical evidence from this study?

Study design: Case Report. Population: Cardiac Amyloidosis (n=1). Intervention: Daratumumab-based chemotherapy (Dara-CyBorD).

What does this research mean for the field?

Advanced AL cardiac amyloidosis can present with ischemic stroke and rapidly progress to multiorgan failure and death despite daratumumab-based chemotherapy. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This case examines the challenges in diagnosing cardiac amyloidosis in a young patient presenting with an ischemic stroke and systemic symptoms.

August 2, 2026CureusOpen Access

From Stroke to the Final Diagnosis: Cardiac Amyloidosis

View Full Paper

Ask AI

Bookmark

Key result

AL cardiac amyloidosis presenting as ischemic stroke rapidly progresses to fatal multiorgan failure despite daratumumab.

Why the study?

Cardiac amyloidosis often presents with nonspecific clinical manifestations leading to delayed diagnosis, making early recognition critical especially in patients with extracardiac manifestations.

Population

One 43-year-old woman admitted with ischemic stroke of unknown origin

Design

Case report

Authors

SAShahana AlasgarliAzerbaijan Medical University TNTaleh Naghdaliyev AKAnar Karimkhanov

Discussion

Member takes

Implication

May prompt echocardiography in cryptogenic stroke; leaves open whether early detection improves outcomes.

Key Points

This case examines the challenges in diagnosing cardiac amyloidosis in a young patient presenting with an ischemic stroke and systemic symptoms.
Conducted extensive imaging evaluations including transthoracic and transesophageal echocardiography, electrocardiography, and cardiac magnetic resonance imaging.
Performed renal biopsy to establish diagnosis amid inconclusive serum and urine immunofixation.
Patient was treated with standard heart failure therapy followed by daratumumab-based chemotherapy.
Echocardiography revealed abnormalities suggestive of an infiltrative process, with low QRS voltage and increased ventricular wall thickness.
Cardiac magnetic resonance imaging showed late gadolinium enhancement and elevated T1 values indicative of cardiac amyloidosis.
Patient developed anuric renal failure and multiorgan failure after treatment, leading to death after the second chemotherapy cycle.

Study Design

Type

Case Report (n=1)

Structured PICO

Population

A 43-year-old woman presenting with an ischemic stroke of unknown origin who was subsequently diagnosed with AL cardiac amyloidosis.

Intervention

Daratumumab-based chemotherapy (Dara-CyBorD: daratumumab, cyclophosphamide, bortezomib, and dexamethasone), along with apixaban 5 mg twice daily, metoprolol 12.5 mg twice daily, and dapagliflozin 10 mg once daily.

Outcome

Clinical course and survivalhard clinical

This case highlights the diagnostic value of multimodality imaging in suspected cardiac amyloidosis and emphasizes the importance of considering systemic amyloidosis in younger patients presenting with stroke, nephrotic syndrome, increased ventricular wall thickness, and low QRS voltage.

Cite This Study

Alasgarli et al. (2026) conducted a case report in Cardiac Amyloidosis (n=1). Daratumumab-based chemotherapy (Dara-CyBorD) was evaluated. A 43-year-old woman diagnosed with AL cardiac amyloidosis after presenting with an ischemic stroke rapidly developed multiorgan failure and died despite daratumumab-based chemotherapy.

synapsesocial.com/papers/6a6eeacb1b0468a7eeab3496 https://doi.org/10.7759/cureus.113697

View Full Paper

Ask AI

Bookmark

From Stroke to the Final Diagnosis: Cardiac Amyloidosis

Discussion

Member takes

Implication

Key Points

Study Design

Structured PICO

Cite This Study

From Stroke to the Final Diagnosis: Cardiac Amyloidosis

Discussion

Member takes

Implication

Key Points

Study Design

Structured PICO

Cite This Study

Also Consider

Also Consider